News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A 26-Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26-Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age

Study Status:

Active, Enrolling Participants

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose of this research study is to evaluate the efficacy and safety of the drugs dapagliflozin and saxagliptin in patients with Type 2 Diabetes who are aged 10 to below 18 years old and are currently taking metformin, insulin, or both drugs.

Information: 

Principal Investigator
Marcel Twahirwa, MD
Type of Trial
Prospective
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram